Why the study?
Does enteric-coated aspirin reduce gastroduodenal mucosal lesions compared to plain aspirin or placebo in healthy volunteers?
Population
59 healthy volunteers (18 in study 1, 41 in study 2)
Comparison
Enteric-coated aspirin 100 mg/day for 7 to 15 days vs Placebo or plain aspirin 100 mg/day
Design
RCT, randomized, double-blind
Follow-up
7 to 15 days
Authors
Loading...
Enteric-coated aspirin may be preferred to limit short-term mucosal injury in low-dose users; confirms formulation-dependent effects in RCT evidence.
Does enteric-coated aspirin reduce gastroduodenal mucosal lesions compared to plain aspirin or placebo in healthy volunteers?
Enteric-coated aspirin 100 mg/day causes significantly less endoscopic gastroduodenal damage over 7 days compared to plain aspirin in healthy volunteers.
Dammann et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: